Clinical trials in humans have already shown that immunotherapy treatment (PD-1 antibody) doubles the survival rate in humans.

The PD-1 antibody prevents cancer cells from escaping immune surveillance. Many cancer cells acquire mutations that allow them to survive when they would have otherwise been killed by immune cells.